The DUAL V trial, sponsored by Novo Nordisk, compares the efficacy and safety of insulin degludec/liraglutide (IDegLira) against insulin glargine in patients with type 2 diabetes mellitus. With a global enrollment of 557 participants across 75 sites in 10 countries, the trial's completion in November 2014 positions IDegLira as a competitive option in the basal insulin market, particularly against established therapies like insulin glargine. The integration of GLP-1 receptor agonism with basal insulin may enhance patient adherence and outcomes, potentially capturing a significant share of the diabetes treatment market. The results may influence prescribing patterns and reimbursement strategies, particularly in markets with high diabetes prevalence.